Navigation Links
Skystar Bio-Pharmaceutical Raises 2007 Revenue Guidance to $15.8 Million
Date:1/31/2008

XI'AN, China, Jan. 31 /Xinhua-PRNewswire-FirstCall/ -- Skystar Bio-Pharmaceutical Co., Ltd. (OTC Bulletin Board: SKBI) ("Skystar", "Company"), a leading bio-pharmaceutical company in the People's Republic of China ("PRC"), today announced that the Company is raising its guidance for 2007 revenue to $15.8 million. The Company previously announced 2007 revenue guidance to be in the range of $12 - $14 million.

"We are proud to announce the first year operating our new veterinary medicine facility we exceeded our revenue target for 2007. Our success in achieving our record revenue is the result of expanding our product line with 62 new drug approvals, increasing our market penetration and implementing an aggressive marketing campaign," commented Skystar's Chief Executive Officer, Mr. Weibing Lu. "We look forward to another strong year for 2008 as our new vaccine facility is expected to begin large-scale production in the second half of the year."

About Skystar Bio-Pharmaceutical

Skystar Bio-Pharmaceutical Company is a China-based producer and distributor of vaccines, microorganisms and veterinary medication to cure and prevent disease in poultry, livestock, birds and pets. The Company's product line consists of more than 100 products with over 50 additional products in the developmental stage. Skystar has formed strategic sales distribution networks throughout China. The Company recently completed construction of new state-of-the-art bio-pharmaceutical facilities covering an area of almost eight acres. The new facilities meet or exceed all Good Manufacturing Practice (GMP) Certification Standards and have received GMP Certification from the Chinese government. For additional information, please visit http://www.skystarbio-pharmaceutical.com .

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: This press release contains certain "forward-looking statements," as defined in the United States Private Securities Litigation Reform Act of 1995, that involve a number of risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are based upon the current beliefs and expectations of management and are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Such factors include, but are not limited to the Company's ability to develop new products, market acceptance of the company's new products, ability to obtain the regulatory approvals or clearances that are necessary to commercialize its products, ability to protect proprietary rights, political and economic factors in the People's Republic of China and other factors detailed from time to time in the Company's filings with the United States Securities and Exchange Commission and other regulatory authorities. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For more information, please contact:

Scott Cramer

Director - U.S. Representative

Skystar Bio-Pharmaceutical Co., Ltd.

Tel: +1-407-645-4433

Email: scramer@skystarbio-pharmaceutical.com

Crocker Coulson, President

CCG Elite Investor Relations

Email: crocker.coulson@ccgir.com

Leslie Richardson, Financial Writer

CCG Elite Investor Relations

Tel: 310-231-8600 x 122

Email: leslie.richardson@ccgir.com


'/>"/>
SOURCE Skystar Bio-Pharmaceutical Co., Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
2. Pearl Therapeutics Raises $15.5 Million in Private Financing
3. Enobia Pharma Raises $40.1 Million Series B Financing
4. Cardiosolutions Raises $7 Million for Spacer Technology to Mitigate Mitral Regurgitation
5. MannKind Corporation Raises $250 Million in Self Managed Registered Direct Offerings of Common Stock
6. VisEn Medical Raises $7 Million in Series B Financing
7. Thermo Fisher Scientific Reports Record Third Quarter Revenues and Adjusted EPS and Raises Full-Year Guidance
8. Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues
9. Antibody Engineering Company f-star Raises EUR 3.0 Million in a Second Closing of its Series A Financing Round From Novo A/S
10. Perrigo Announces Final FDA Approval of Dexcels OTC Omeprazole; Raises Full Year Earnings Guidance
11. Anesiva Raises $45 Million in Common Stock Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... ... May 31, 2016 , ... Adimarket, a ... and approved SVF closed system kit using EmCyte technology, and is expected to be ... to process adipose tissue and obtain stromal vascular fraction (SVF) in a closed environment. ...
(Date:5/31/2016)... ... May 30, 2016 , ... Doctors in Italy say ... live longer than patients with lower levels. Surviving Mesothelioma has just posted an article ... at cancer centers in Genoa and La Spezia, Italy tested the blood serum, tumors, ...
(Date:5/27/2016)... , ... May 27, 2016 , ... PBI-Gordon Corporation is ... and Ornamental Products. , In his 15-year career with PBI-Gordon, Dave has served in ... where he was integral in the development and launch of many of PBI-Gordon’s most ...
(Date:5/26/2016)... and READING, England , ... ( http://www.indegene.com ), a leading global provider of ... pharmaceutical and healthcare organisations and TranScrip ( http://www.transcrip-partners.com ... support throughout the product lifecycle, today announced the ... of IntraScience.      (Logo: http://photos.prnewswire.com/prnh/20141208/720248 ...
Breaking Biology Technology:
(Date:5/24/2016)... , May 24, 2016 Ampronix facilitates superior patient care by providing unparalleled ... medical LCD display is the latest premium product recently added to the range of ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
(Date:5/20/2016)... 2016  VoiceIt is excited to announce its ... By working together, VoiceIt and VoicePass will ... VoicePass take slightly different approaches to voice biometrics, ... and usability. ... partnership. "This marketing and technology partnership ...
(Date:5/16/2016)...   EyeLock LLC , a market leader of ... an IoT Center of Excellence in Austin, ... of embedded iris biometric applications. EyeLock,s iris ... security with unmatched biometric accuracy, making it the most ... EyeLock,s platform uses video technology to deliver a fast ...
Breaking Biology News(10 mins):